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Abstract
Background: Silicon is the element most similar to carbon, and
bioactive organosilanes have therefore been of longstanding
interest. Design of bioactive organosilanes has often involved a
systematic replacement of a bioactive molecule’s stable carbon
atoms with silicon. Silanediols, which are best known as unstable
precursors of the robust and ubiquitous silicone polymers, have
the potential to mimic an unstable carbon, the hydrated carbonyl.
As a bioisostere of the tetrahedral intermediate of amide
hydrolysis, a silanediol could act as a transition state analog
inhibitor of protease enzymes.
Results : Silanediol analogs of a carbinol-based inhibitor of the
HIV protease were prepared as single enantiomers, with up to six
stereogenic centers. As inhibitors of this aspartic protease, the
silanediols were nearly equivalent to both their carbinol analogs
and indinavir, a current treatment for AIDS, with low nanomolar
Ki values. IC90 data from a cell culture assay mirrored the Ki data,
demonstrating that the silanediols can also cross cell membranes
and deliver their antiviral effects.
Conclusions: In their first evaluation as inhibitors of an aspartic
protease, silanediol peptidomimetics have been found to be nearly
as potent as currently available pharmaceutical agents, in enzyme
and cell protection assays. These neutral, cell-permeable transition
state analogs therefore provide a novel foundation for the design
of therapeutic agents. ß 2001 Elsevier Science Ltd. All rights
reserved.
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1. Introduction
Proteolytic enzymes mediate many key biological events
by hydrolyzing speci¢c peptide bonds (1C3+4), and have
thereby achieved a prominent position in the hierarchy of
pharmaceutical targets [1]. Inhibitors of angiotensin-con-
verting enzyme currently play a major role in the control
of hypertension [2], and inhibitors of the HIV protease
have proven to be potent tools for the control of AIDS
[3,4]. Proteases are intimately involved in cancer [5] and
apoptosis [6,7], and their e¡ects are manifest in diseases as
diverse as anthrax [8,9], cystic ¢brosis [10], and Alzhei-
mer’s disease [11]. E⁄cacious in vivo inhibitors for many
of these targets, however, remain elusive.
At the center of protease inhibitor design, the ¢rst step
in creation of a new therapeutic agent is selection of a
nonhydrolyzable analog of 2, the tetrahedral intermediate
of amide hydrolysis (Fig. 1). Enzyme binding of the ener-
getically disfavored 2, through Coulombic interactions,
solvation, and hydrogen bonding, results in dramatic ac-
celerations in the rate of hydrolysis of 1 [12]. Nonhydro-
lyzable isosteres of 2, when bound at the catalytic site of
the enzyme, inhibit proteolysis and can thereby eliminate
the biological consequences of that proteolytic action.
The diversity of inhibitor designs available to the medic-
inal chemist, however, is limited by the small number of
unique isosteres of 2. For aspartic proteases, these iso-
steres include carbinols, ketones, and phosphinic acids
(5^7), each with its characteristic attributes of size, shape
and charge distribution. Testing of compounds containing
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these isosteres against the HIV protease have found only
carbinols to be highly e¡ective [3,13,14]. Silanediols are
well known chemical structures, but silanediols such as 8
have never been prepared. This may be because simpler
silanols have been found to be ine¡ective as inhibitors of
hydrolase enzymes [15,16], as well as the general knowl-
edge that silanediols readily polymerize [17]. We describe
here the ¢rst example of a silanediol designed as an as-
partic protease inhibitor, the demonstration of its e¡ec-
tiveness against the HIV protease and its ability to sup-
press the virus in whole cell assays.
2. Results
Silicon is the element most similar to carbon but di¡ers
dramatically from carbon in its ability to accommodate
double bonds. The carbon^oxygen double bonds in 1 are
very strongly favored over the hydrated form 2. As a point
of comparison, the carbon^oxygen double bond of ace-
tone 9 (Fig. 2, X = C) is more readily hydrated than
1 but remains less than 0.01% hydrated 10 in aqueous
solution. In contrast, formation of a silicon^oxygen dou-
ble bond is extremely disfavored over its hydrate, the si-
lanediol 10 (X = Si). A silanediol can therefore be consid-
ered to be an analog of the unstable hydrated carbonyl 2.
The simplest and best known silanediol, dimethylsilane-
diol 10 (X = Si), is intrinsically unstable toward dehydra-
tion/polymerization, forming permethylsilicone 11. Ap-
proximately one million tons of this silanediol are
synthesized each year to make silicone polymers [18].
More sterically hindered silanediols are stable, but unlike
the silanediols reported here, the known silanediols are
composed solely of simple alkyl and aryl groups [19].
Silanediol-based dipeptide analogs like 8 are new chem-
ical species, more complex than any silanediol previously
described. We expected that the steric shielding of the
organic substituents in 8 would disfavor formation of olig-
omers. Silanols are equivalent to carbinols like 5 in their
capacity to accept hydrogen bonds, and are better hydro-
gen bond donors [20]. These are ideal attributes for inter-
action with the active site of aspartic proteases, where two
carboxylic acid residues stabilize intermediate 2 through
hydrogen bonding. To assess the e¡ectiveness of silane-
diols as aspartic protease inhibitors, we have prepared
the C2 symmetric 17 (Fig. 3), an analog of the potent
HIV protease inhibitor, carbinol 18 [21].
Our synthetic approach to silanediol 17 utilized diphe-
nylsilane 15 as a key intermediate, unveiling the poten-
tially polymerizable silanediol group by acid-catalyzed hy-
drolysis of the aryl^silicon bonds in the last synthetic step.
Acidic aryl silane hydrolysis was anticipated to be com-
patible with the surrounding functionality since similar
conditions have been used for polypeptide deprotection
[22]. Synthesis of 15 began with enantiomerically pure io-
dide (S)-12 [23], which was converted to the lithium re-
agent 13 by metal^halogen exchange [24,25]. Coupling of
this lithium reagent with slightly less than one-half of an
equivalent of dichlorodiphenylsilane gave the correspond-
ing (S,S)-dialkyldiphenylsilane in 98% yield. Cleavage of
the benzyl ethers with boron tribromide led to the diol 14
(93%). Oxidation of the diol to the dialdehyde using Swern
conditions [26], followed by oxidation with potassium per-
manganate [27], gave the diacid in 94% yield for two steps.
Diamides 15 were formed by coupling the diacid with
benzyl amine and with 1-(S)-2-(R)-1-amino-2-indanol us-
ing diethyl phosphorocyanidate as an activating agent [28]
to give diamides 15a and 15b, isolated in 62% and 75%
yields, respectively.
The critical deprotection of diphenylsilanes 15a and 15b
was performed with an excess of tri£uoromethanesulfonic
acid (tri£ic acid). This transformation can be followed by
1H NMR spectroscopy and involves a symmetric inter-
mediate, believed to be spirocycle 16. Intermediate 16
would be formed by amide-assisted cleavage of the phe-
nyl^silicon bonds. This intermediate is hydrolytically un-
stable [29] and treatment with ammonium hydroxide pro-
vided the desired silanediols 17a and 17b as colorless solids
in 40^80% yield after puri¢cation.
Table 1 shows the results from evaluation of silanediols
Fig. 1. Tetrahedral intermediate 2 can be replaced by nonhydrolyzable 5^7, resulting in protease inhibitors. New analog 8.
Fig. 2. Carbon, but not silicon, forms strong double bonds to oxygen.
CHBIOL 143 12-12-01 Cyaan Magenta Geel Zwart
1162 Chemistry & Biology 8/12 (2001) 1161^1166
17a and 17b, and carbinols 18a and 18b as HIV protease
inhibitors using an assay described previously [30], with
indinavir 19 [31] as a benchmark. The two benzyl amides,
silanediol 17a and carbinol 18a, gave identical, low micro-
molar Ki values, indicating a signi¢cant level of enzyme
binding. The equivalence of these inhibitors established,
for the ¢rst time, that silanediols can be as e¡ective as
carbinols [13], the central component of all commercial
aspartic protease inhibitor drugs.
The use of the (1S,2R)-1-amino-2-indanol as amide
groups in 17b and 18b dramatically enhanced the enzyme
inhibition, with the Ki for carbinol 18b lowered by nearly
104 compared to 18a. Silanediol 17b binds to the enzyme
nearly as well as the carbinol 18b, with a Ki of 2.7 nM.
The binding data for both 17b and 18b compare very
favorably with the established HIV therapeutic agent in-
dinavir 19, which has a Ki of 0.37 nM in this assay.
Cell culture is a more rigorous evaluation of therapeutic
potential, because antiviral activity can be demonstrated
only after the inhibitor crosses cell membranes. The IC90
values in Table 1 are the concentration of compound caus-
ing a 90% reduction in virus replication relative to un-
treated control infections [32]. For silanediol 17b and car-
binols 18b and 19, this IC90 value parallels the enzyme Ki
values. Addition of serum protein to these assays, to probe
the e¡ect of nonspeci¢c protein binding that can impact
bioavailability in vivo [33], does not alter the relative e⁄-
cacy of the silanediol as an antiviral agent.
The consistency of these data is remarkable. Comparing
the Ki values for 17b and 18b, the carbinol 18b is more
active than the silanediol 17b by a factor of 7.1, while the
IC90 values di¡er by a factor of 7.4. Silanediol 17b con-
tains the same skeleton as carbinol 18b, the latter being
highly optimized for the HIV protease active site [21]. The
seven-fold di¡erence in activity between silanediol 17b and
carbinol 18b may be due to the size of the silicon atom in
the inhibitor backbone. The silicon^carbon bond is 20%
longer than a carbon^carbon bond (1.88 Aî vs. 1.54 Aî ).
Three-dimensional structures for the tetrahedral inter-
mediate (A), the hydroxyethylene group (B), and the sila-
nediol (C) are shown in Fig. 4. Not only is silanediol C
larger than A and B, it has a more pronounced surface
charge distribution that could accentuate Coulombic and
dipolar interactions at the active site.
3. Signi¢cance
The silanediol functional group is a new bioisostere of
the hydrated amide carbonyl. It is neutral, cell-permeable,
and the outstanding hydrogen bonding of silanols allows
for good interactions with the active site of aspartic pro-
Fig. 3. Synthesis of silanediols 17a and 17b.
Table 1
Enzyme inhibition (Ki, light bars) and cell protection (IC90, dark bars)
data for silanediols 17, and carbinols 18, and indinavir 19
Ki data were determined using assay system C described in [30]. IC90
antiviral activity was determined in a cell-based system described in
reference [32].
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teases. The e⁄cacy of a silanediol as an HIV protease
inhibitor, at concentrations within an order of magnitude
of the therapeutically e¡ective agent indinavir, demon-
strates for the ¢rst time that a silicon-based transition
state analog can be a centerpiece of aspartic protease in-
hibitor design. In conjunction with our recent report of an
e¡ective silanediol-based metalloprotease inhibitor [34], it
is clear that silanediols can be potent and generally appli-
cable inhibitors across several protease enzyme classes.
Moreover, the e¡ective antiviral properties of silanediol
17b in cell culture indicate that these structures have the
potential to be the basis of new pharmaceutical agents.
The competency of these silanediol inhibitors contrasts
with previous reports in which silanediol [15] and silane-
triols [16] did not inhibit hydrolase enzymes, and is also at
variance with the perception that silanediols are unstable,
problematic chemical entities. Extending the application of
silanediols to the inhibition of other proteases and other
protease classes will serve to further de¢ne the breadth of
this new medicinal chemistry tool, and will be reported in
due course.
4. Materials and methods
4.1. N,NP-Dibenzyl 2-(S)-6-(S)-dibenzyl-4,4-diphenyl-4-sila-
heptane-diamide (15a)
To a solution of 2-(S)-6-(S)-dibenzyl-4,4-diphenyl-4-sila-hepta-
nedioic acid (228 mg, 0.45 mmol) in DMF (5 ml) at 0‡C was
consecutively added benzylamine (0.12 ml, 1.13 mmol), DPPA
(0.24 ml, 1.13 mmol), and triethylamine (0.28 ml, 2.03 mmol).
The reaction mixture was stirred at 0‡C for 2 h and then warmed
to room temperature overnight. The mixture was diluted with 10
ml ethyl acetate and washed successively with 5% aqueous HCl,
water, saturated aqueous sodium bicarbonate, and saturated
aqueous NaCl. After drying over MgSO4 and ¢ltering, the solu-
tion was concentrated in vacuo. Flash chromatography (7:3 hex-
ane/ethyl acetate) a¡orded 15a as a foam (189 mg, 62%).
Rf = 0.26 (7:3 hexane/ethyl acetate) ; mp 55^60‡C; 1H NMR
(CDCl3) N 7.47^6.79 (m, 30 H), 5.56 (t, 2 H), 4.31 (dd, 2 H,
J = 14.7 Hz and 6.7 Hz), 3.82 (dd, 2 H, J = 14.7 Hz and 4.5
Hz), 2.87 (dd, 2 H, J = 13.2 Hz and 10.2 Hz), 2.55 (dd, 2 H,
J = 13.2 Hz and 4.7 Hz), 2.42 (m, 2 H), 1.68 (dd, 2 H, J = 15.0
Hz and 7.4 Hz), 1.48 (dd, 2 H, J = 15.0 Hz and 6.6 Hz); 13C
(CDCl3) N 175.2, 139.8, 137.7, 135.4, 134.7, 129.7, 128.9, 128.4,
128.3, 128.1, 127.6, 127.2, 126.2, 45.3, 43.2, 41.5, 15.8; IR
(CH2Cl2) 3318, 1648, 1542, 1495, 1453, 1427, 1242, 1108, 739,
698 cm31 ; exact mass (FAB) calcd. for C46H47N2O2Si (MH)
687.3407, found: 687.3414.
4.2. N,NP-Bis[(2R)-hydroxy-indan-1-yl] 2-(S)-6-(S)-dibenzyl-
4,4-diphenyl-4-sila-heptanediamide (15b)
To a solution of 2-(S)-6-(S)-dibenzyl-4,4-diphenyl-4-sila-hepta-
nedioic acid (529 mg, 1.04 mmol) and (1S,2R)-1-amino-2-indanol
(373 mg, 2.50 mmol) in DMF (10 ml) at 0‡C was consecutively
added DEPC (0.38 ml, 2.50 mmol), and triethylamine (0.64 ml,
4.58 mmol). The reaction mixture was stirred at 0‡C for 2 h and
then warmed to room temperature overnight. The mixture was
diluted with 10 ml ethyl acetate and washed successively with 5%
aqueous HCl, water, saturated aqueous sodium bicarbonate, and
saturated aqueous NaCl. After drying over MgSO4 and ¢ltering,
the solution was concentrated in vacuo. Flash chromatography
Fig. 4. Molecular models of the tetrahedral intermediate of peptide hydrolysis A, the classic carbinol isostere B and the new silicon-based analog C rep-
resented as ball and stick models inside the molecular surfaces. Surface colors indicate the calculated electron densities. These structures were calculated
using the semiempirical method PM3, with geometry optimization, using MacSPARTAN (Wavefunction, Irvine, CA, USA).
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(6:4 hexane/ethyl acetate) a¡orded 15b as a foam (602 mg, 75%).
Rf = 0.25 (6:4 hexane/ethyl acetate); mp 73^77‡C; 1H (CDCl3)
N 7.64^6.75 (m, 28 H), 5.63 (d, 2 H, J = 8.4 Hz), 5.03 (dd, 2 H,
J = 4.2 Hz and 8.1 Hz), 4.11 (m, 2 H), 2.87 (dd, 2 H, J = 5.4 Hz
and 6.6 Hz), 2.85 (dd, 2 H, J = 5.1 Hz and 5.4 Hz), 2.70 (m, 4 H),
2.58 (m, 2 H), 1.88 (dd, 2 H, J = 7.5 Hz and 15.0 Hz), 1.63 (dd,
2 H, J = 6.6 Hz and 15.0 Hz), 1.3 (m, 2 H); 13C (CDCl3) N 175.7,
140.2, 140.0, 139.9, 135.1, 134.8, 129.8, 129.0, 128.5, 128.2, 127.8,
126.7, 126.5, 124.9, 123.9, 72.9, 57.4, 45.5, 42.1, 38.7, 16.1; IR
(KBr) 3322, 3021, 2915, 1648, 1510, 736, 700 cm31.
4.3. N,NP-Dibenzyl 2-(S)-6-(S)-dibenzyl-4,4-dihydroxy-4-sila-
heptane-diamide (17a)
To a solution of diamide 15a (166.7 mg, 0.243 mmol) in 10 ml
methylene chloride at room temperature was added fresh distilled
tri£uoromethanesulfonic acid (0.22 ml, 2.43 mmol). After stirring
at room temperature for 60 min, the mixture was cooled to 0‡C
and 14.8 N NH4OH (0.25 ml, 3.64 mmol) was added. The mix-
ture was stirred at 0‡C for another 30 min then washed with
water (10 ml) (aqueous layer pH = 8) and saturated aqueous
NaCl (10 ml). The organic layer was dried over MgSO4, ¢ltered,
and concentrated to give silanediol 17a (137.7 mg, 0.243 mmol,
100%); Rf = 0.18 (5:1 benzene/acetone); 1H NMR (DMSO-d6)
N 8.02 (t, 2 H, J = 5.4 Hz), 7.23^6.81 (m, 20 H), 4.31 (dd, 2 H,
J = 15 Hz and 6.6 Hz), 3.90 (dd, 2 H, J = 15 Hz and 4.8 Hz),
2.81^2.79 (m, 6 H), 0.93^0.89 (m, 4 H); 13C NMR (DMSO-d6)
N 175.8, 175.6, 175.5, 140.7, 140.5, 140.4, 139.5, 139.4, 139.3,
129.1, 129.0, 128.2, 127.1, 127.0, 126.6, 125.9, 42.9, 42.8, 42.7,
41.8, 40.5, 40.2, 20.4, 19.9, 19.8; IR (KBr) 3396, 1647, 1541,
1496, 1455, 1384, 1246, 1076, 891, 741, 698 cm31.
4.4. N,NP-Bis[(2R)-hydroxy-indan-1-yl] 2-(S)-6-(S)-dibenzyl-
4,4-dihydroxy-4-sila-heptanediamide (17b)
To a solution of diamide 15b (62 mg, 0.08 mmol) in methylene
chloride (3 ml) at room temperature was added freshly distilled
tri£uoromethanesulfonic acid (0.14 ml, 1.6 mmol). After stirring
at room temperature for 40 min, the mixture was cooled to 0‡C
and 14.8 N NH4OH (0.16 ml, 2.4 mmol) was added. The mixture
was stirred at 0‡C for another 30 min then ¢ltered and the solid
was washed with methylene chloride (2 ml) followed by water (5
ml). Drying under the vacuum overnight provided silanediol 17b
(19.2 mg, 0.03 mmol, 37%); 1H NMR (DMSO-d6) N 7.61 (d, 2 H,
J = 8.6 Hz), 7.27^6.95 (m, 18 H), 6.05 (br, 2 H), 5.04 (dd, 2 H,
J = 4.8 Hz and 12.8 Hz), 4.60 (d, 2 H, J = 3.5 Hz), 4.22 (m, 2 H),
2.90^2.66 (m, 10 H), 0.91 (dd, 2 H, J = 6.5 Hz and 15.1 Hz), 0.70
(dd, 2 H, J = 6.5 Hz and 14.5 Hz); 13C NMR (DMSO-d6) N 176.1,
142.2, 140.7, 140.6, 129.0, 128.1, 127.0, 126.0, 125.8, 124.7, 124.2,
72.2, 56.7, 42.5, 40.2, 39.7; IR (KBr) 1638, 1618, 1526, 1400,
1384, 1259, 1178, 1036, 982, 886, 750, 704, 648 cm31.
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